Effects of LAMA/LABA Alone and in Combination on Cardiac Safety.
作者信息
Andreas Stefan
机构信息
Department of Cardiology and Pneumology, University Medical Centre Göttingen, Göttingen, Germany.
LungClinic Immenhausen, Immenhausen, Germany, Member of the German Center for Lung Research (DZL).
出版信息
Int J Chron Obstruct Pulmon Dis. 2020 Aug 10;15:1931-1933. doi: 10.2147/COPD.S246356. eCollection 2020.
Abstract
摘要
相似文献
1
Effects of LAMA/LABA Alone and in Combination on Cardiac Safety.长效抗胆碱能药物/长效β2受体激动剂单用及联用对心脏安全性的影响。
Int J Chron Obstruct Pulmon Dis. 2020 Aug 10;15:1931-1933. doi: 10.2147/COPD.S246356. eCollection 2020.
2
Comparative Cardiovascular and Cerebrovascular Safety of Inhaled Long-Acting Bronchodilators in Patients with Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study.慢性阻塞性肺疾病患者吸入长效支气管扩张剂的心血管和脑血管安全性比较：一项基于人群的队列研究。
Pharmacotherapy. 2016 Jan;36(1):26-37. doi: 10.1002/phar.1684.
3
Efficacy and Safety of LAMA/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment Comparisons.LABA/LAMA 固定剂量联合治疗在慢性阻塞性肺疾病中的疗效和安全性：直接和间接治疗比较的系统评价。
Int J Chron Obstruct Pulmon Dis. 2020 Jul 1;15:1529-1543. doi: 10.2147/COPD.S230955. eCollection 2020.
4
A safety comparison of LABA+LAMA vs LABA+ICS combination therapy for COPD.LABA+LAMA 与 LABA+ICS 联合治疗 COPD 的安全性比较。
Expert Opin Drug Saf. 2018 May;17(5):509-517. doi: 10.1080/14740338.2018.1448786. Epub 2018 Mar 8.
5
A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD.一项关于长效抗胆碱能药物/长效β2受体激动剂双重支气管扩张治疗稳定期慢性阻塞性肺疾病的系统评价与荟萃分析
Chest. 2016 May;149(5):1181-96. doi: 10.1016/j.chest.2016.02.646. Epub 2016 Feb 26.
6
Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.在 ICS/LABA 治疗中添加 LAMA：COPD 三联疗法的荟萃分析。
Chest. 2019 Apr;155(4):758-770. doi: 10.1016/j.chest.2018.12.016. Epub 2019 Jan 17.
7
Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice.在真实临床实践中，LABA-LAMA 与 LABA-ICS 治疗 COPD 的疗效和安全性比较。
Chest. 2019 Jun;155(6):1158-1165. doi: 10.1016/j.chest.2019.03.005. Epub 2019 Mar 26.
8
Impact of LABA/LAMA combination on exercise endurance and lung hyperinflation in COPD: A pair-wise and network meta-analysis.长效β2受体激动剂/长效抗胆碱能药物联合使用对慢性阻塞性肺疾病运动耐力和肺过度充气的影响：一项成对和网状荟萃分析。
Respir Med. 2017 Aug;129:189-198. doi: 10.1016/j.rmed.2017.06.020. Epub 2017 Jun 29.
9
Comparative Effects of LAMA-LABA-ICS vs LAMA-LABA for COPD: Cohort Study in Real-World Clinical Practice.LAMA-LABA-ICS 与 LAMA-LABA 治疗 COPD 的对比效果：真实世界临床实践中的队列研究。
Chest. 2020 Apr;157(4):846-855. doi: 10.1016/j.chest.2019.11.007. Epub 2019 Nov 22.
10
Role of Long-Acting Muscarinic Antagonist/Long-Acting β-Agonist Therapy in Chronic Obstructive Pulmonary Disease.长效毒蕈碱拮抗剂/长效β受体激动剂疗法在慢性阻塞性肺疾病中的作用
Ann Pharmacother. 2017 Aug;51(8):696-705. doi: 10.1177/1060028017705149. Epub 2017 Apr 14.
引用本文的文献
1
Systemic Manifestations of COPD and the Impact of Dual Bronchodilation with Tiotropium/Olodaterol on Cardiac Function and Autonomic Integrity.慢性阻塞性肺疾病的全身表现以及噻托溴铵/奥达特罗双重支气管扩张对心脏功能和自主神经完整性的影响。
J Clin Med. 2024 May 16;13(10):2937. doi: 10.3390/jcm13102937.
2
Towards Rational Prescription of Common Inhaler Medication in the Multimorbid COPD Patient.面向多合并症 COPD 患者的常见吸入药物合理处方。
Int J Chron Obstruct Pulmon Dis. 2021 May 11;16:1315-1327. doi: 10.2147/COPD.S298345. eCollection 2021.
本文引用的文献
1
A Post Hoc Holter ECG Analysis of Olodaterol and Formoterol in Moderate-to-Very-Severe COPD.中度至极重度 COPD 中奥达特罗和福莫特罗的事后 Holter ECG 分析。
Int J Chron Obstruct Pulmon Dis. 2020 Aug 10;15:1955-1965. doi: 10.2147/COPD.S246353. eCollection 2020.
2
No Influence on Cardiac Arrhythmia or Heart Rate from Long-Term Treatment with Tiotropium/Olodaterol versus Monocomponents by Holter ECG Analysis in Patients with Moderate-to-Very-Severe COPD.通过动态心电图分析比较噻托溴铵/奥达特罗与单一组分长期治疗对中重度至极重度慢性阻塞性肺疾病（COPD）患者心律失常或心率的影响
Int J Chron Obstruct Pulmon Dis. 2020 Aug 10;15:1945-1953. doi: 10.2147/COPD.S246350. eCollection 2020.
3
Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD.噻托溴铵/奥达特罗与单一组分相比对中重度至极重度 COPD 患者长期心率和血压的无不良影响。
Int J Chron Obstruct Pulmon Dis. 2020 Aug 10;15:1935-1944. doi: 10.2147/COPD.S246348. eCollection 2020.
4
Systematic literature review and meta-analysis of US-approved LAMA/LABA therapies versus tiotropium in moderate-to-severe COPD.对美国批准的 LAMA/LABA 疗法与噻托溴铵治疗中重度 COPD 的系统文献回顾和荟萃分析。
NPJ Prim Care Respir Med. 2018 Aug 27;28(1):32. doi: 10.1038/s41533-018-0099-1.
5
Effect of long-acting β-agonists olodaterol and formoterol on heart rate and blood pressure in chronic obstructive pulmonary disease patients.长效β-激动剂奥达特罗和福莫特罗对慢性阻塞性肺疾病患者心率和血压的影响。
Pulm Pharmacol Ther. 2018 Oct;52:1-6. doi: 10.1016/j.pupt.2018.08.002. Epub 2018 Aug 2.
6
Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events.COPD 中长效支气管扩张剂的联合使用与不良心血管事件风险。
Eur Respir J. 2017 May 23;49(5). doi: 10.1183/13993003.02245-2016. Print 2017 May.
7
Long-term general and cardiovascular safety of tiotropium/olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease.噻托溴铵/奥达特罗在中度至极重度慢性阻塞性肺疾病患者中的长期总体安全性及心血管安全性
Respir Med. 2017 Jan;122:58-66. doi: 10.1016/j.rmed.2016.11.011. Epub 2016 Nov 14.
8
The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline.德国慢性阻塞性肺疾病队列研究COSYCONET：研究目的、方法及基线研究人群的描述性分析
Respir Med. 2016 May;114:27-37. doi: 10.1016/j.rmed.2016.03.008. Epub 2016 Mar 11.
9
Cardiac effects of current treatments of chronic obstructive pulmonary disease.慢性阻塞性肺疾病治疗的心脏效应。
Lancet Respir Med. 2016 Feb;4(2):149-64. doi: 10.1016/S2213-2600(15)00518-4. Epub 2016 Jan 12.
10
Comparative safety and effectiveness of long-acting inhaled agents for treating chronic obstructive pulmonary disease: a systematic review and network meta-analysis.长效吸入剂治疗慢性阻塞性肺疾病的比较安全性和有效性：一项系统评价和网状Meta分析
BMJ Open. 2015 Oct 26;5(10):e009183. doi: 10.1136/bmjopen-2015-009183.
Zotero 插件